Novel Breast Cancer Treatment by Targeting Estrogen Receptor-Alpha Stability Using Proteolysis-Targeting Chimeras (PROTACs) Technology
Main Article Content
ABSTRACT
Approximately 70% of breast cancer cases are estrogen receptor-alpha-positive (ERα+). The binding of estradiol to the ligand-binding domain activates ERα. ERα can also be activated via the phosphorylation induced by growth factors. Activated ERα functions as a transcriptional regulator with a pro-tumor activity in breast cancer cells. In recent years, it has been discovered that some proteins can stabilize ERα by inhibiting its degradation via the ubiquitin-proteasome system through several mechanisms, including ERα monoubiquitination, deubiquitination, or phosphorylation, among others. Herein, we review the proteins associated with the inhibition of ERα degradation and discuss the role of proteolysis-targeting chimeras (PROTACs) as promising therapeutic strategies for breast cancer by inducing ERα degradation. The knowledge of the multiple mechanisms that stabilize ERα protein may be central for the development of new PROTACs for novel breast cancer treatments.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.